← Back to Search

Pacing for Hypocalcemia (DIAGNOSE CRDS Trial)

N/A
Recruiting
Led By Jason D Roberts, MD MAS
Research Sponsored by Population Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants
Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of pacing maneuver
Awards & highlights

DIAGNOSE CRDS Trial Summary

This trial aims to find a new way to diagnose a condition called Calcium Release Deficiency Syndrome (CRDS). CRDS is a rare genetic condition that increases the risk of sudden cardiac death. Currently,

Who is the study for?
This trial is for individuals suspected to have Calcium Release Deficiency Syndrome (CRDS), a genetic heart rhythm disorder that can lead to sudden cardiac death. Participants should be able to undergo a diagnostic test involving brief, controlled increases in heart rate.Check my eligibility
What is being tested?
The study aims to evaluate if CRDS can be diagnosed without cellular tests by observing the heart's electrical recovery after it is briefly sped up using a method called pacing. This could simplify and speed up diagnosis.See study design
What are the potential side effects?
Pacing involves temporarily increasing the heart rate, which may cause discomfort, dizziness, or palpitations during the procedure. However, these effects are typically short-lived and resolve once normal rhythm is restored.

DIAGNOSE CRDS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a genetic mutation in RyR2 or CASQ2 that affects my heart.
Select...
I had a cardiac arrest that remains unexplained even after several heart tests.
Select...
I am scheduled for a detailed heart rhythm test.
Select...
My tests show a specific genetic change that doesn't work properly.
Select...
I have been genetically tested for the RyR2 mutation.

DIAGNOSE CRDS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of pacing maneuver
This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of pacing maneuver for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ΔQT value
ΔT-wave amplitude value
Secondary outcome measures
Absolute QT value
Absolute T-wave amplitude

DIAGNOSE CRDS Trial Design

1Treatment groups
Experimental Treatment
Group I: PacingExperimental Treatment1 Intervention
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pacing
2019
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Population Health Research InstituteLead Sponsor
156 Previous Clinical Trials
680,732 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,349 Previous Clinical Trials
26,458,625 Total Patients Enrolled
Ziv Dadon, MDStudy DirectorShaare Zedek Medical Center
~206 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top